Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

72
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
72
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Introduction to Hemostasis01:05

Introduction to Hemostasis

10.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
10.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

781
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
781
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroacupuncture modulates gut-lung microbiota and lung EMT to attenuate airway remodeling in COPD.

Frontiers in microbiology·2026
Same author

Glucagon-like peptide-1 receptor agonists across anti-inflammation.

Molecular aspects of medicine·2026
Same author

Autonomic nervous system dysfunction in chronic obstructive pulmonary disease: mechanistic insights and therapeutic implications.

Annals of medicine·2025
Same author

Heparin against inflammation: Targeting evolution and clinical impacts.

Annales pharmaceutiques francaises·2025
Same author

[Effect of electroacupuncture on intestinal flora in COPD rats based on gut-lung axis theory].

Zhongguo zhen jiu = Chinese acupuncture & moxibustion·2025
Same author

Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.

Advanced pharmaceutical bulletin·2025

Related Experiment Video

Updated: Oct 29, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.1K

Heparin beyond anti-coagulation.

Daohong Chen1

  • 1Research Institute, Changshan Biochemical Pharmaceutical, North Head of Yinchuan Street, Zhengding New District, Shijiazhuang, Hebei, 050800, China.

Current Research in Translational Medicine
|July 8, 2021
PubMed
Summary

Heparin, a long-used anticoagulant, shows new promise beyond blood thinning. Research explores its effectiveness in treating conditions like respiratory inflammation and COVID-19, highlighting its potential for medical re-purposing.

Keywords:
HeparinMedical re-purposeNon-anticoagulant efficacy

More Related Videos

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

8.1K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

200

Related Experiment Videos

Last Updated: Oct 29, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.1K
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

8.1K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

200

Area of Science:

  • Pharmacology and Medicine

Background:

  • Heparin has been a primary anticoagulant for over 80 years.
  • Heparin derivatives are crucial in managing thrombotic events in conditions like venous thromboembolism and coronary artery disease.

Purpose of the Study:

  • To provide a comprehensive update on the expanded clinical applications of heparin agents.
  • To explore the potential of heparin in medical re-purposing for severe illnesses.

Main Methods:

  • Review of recent clinical studies and investigations.
  • Analysis of off-label efficacious potentials of heparin beyond anticoagulation.

Main Results:

  • Emerging evidence supports heparin's efficacy in diverse clinical areas.
  • Heparin is being investigated for applications in pregnancy, respiratory inflammation, renal disease, sepsis, and pancreatitis.

Conclusions:

  • Heparin exhibits significant potential for medical re-purposing.
  • Heparin can address unmet clinical needs in severe diseases, including COVID-19, by expanding its therapeutic applications.